FDA has granted accelerated approval to pembrolizumab (Keytruda) for patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
